Active Apolipoprotein C3 (APOC3)

Catalog#:PXM12768

概述（Summary）

别称（Alternative Names）	Apo-C3; APOCIII; APOC-III
纯度（Purity）	Greater than 95% as determined by reducing SDS-PAGE.
内毒素（Endotoxin level）	Please contact with the lab for this information
蛋白构建（Construction）	【Glu21-Ser99】
Accession #	P33622
表达宿主（Host）	-
种属（Species）	Mus musculus (Mouse)
预测分子量（Predicted MW）	10.4 kDa
制剂（Form）	Lyophilized from a 0.2 μm filtered solution of 20mM Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose and Proclin300.
运输方式（Shipping）	The product is shipped with ice bag. Upon receipt, store it immediately at the temperature listed below.
稳定性&储存（Stability &Storage）	12 months at -20°C to -80°C in lyophilized state.6 months at -20°C to -80°C under sterile conditions after reconstitution.7-10 days at 2°C to 8°C under sterile conditions after reconstitution.Please minimize freeze-thaw cycles.
复溶（Reconstitution）	Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
背景介绍（References）	Component of triglyceride-rich very low density lipoproteins (VLDL) and high density lipoproteins (HDL) in plasma. Plays a multifaceted role in triglyceride homeostasis. Intracellularly, promotes hepatic very low density lipoprotein 1 (VLDL1) assembly and secretion; extracellularly, attenuates hydrolysis and clearance of triglyceride-rich lipoproteins (TRLs). Impairs the lipolysis of TRLs by inhibiting lipoprotein lipase and the hepatic uptake of TRLs by remnant receptors. Formed of several curved helices connected via semiflexible hinges, so that it can wrap tightly around the curved micelle surface and easily adapt to the different diameters of its natural binding partners.

电泳图（SDS-PAGE image）



Greater than 95% as determined by reducing SDS-PAGE.

活性图（Bioactivity image）



Figure. The binding activity of APOC3 with PCYOX1. Apolipoprotein C3 (APOC3) also known as apo-CIII is a component of very low density lipoprotein (VLDL). APOC3 inhibits lipoprotein lipase and hepatic lipase; it is thought to inhibit hepatic uptake of triglyceride-rich particles. An increase in apoC-III levels induces the development of hypertriglyceridemia. Some evidences suggest an intracellular role for Apo-CIII in promoting the assembly and secretion of triglyceride-rich VLDL particles from hepatic cells under lipid-rich conditions. Besides, Prenylcysteine Oxidase 1 (PCYOX1) has been identified as an interactor of APOC3, thus a binding ELISA assay was conducted to detect the interaction of recombinant mouse APOC3 and recombinant mouse PCYOX1. Briefly, APOC3 were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100µL were then transferred to PCYOX1-coated microtiter wells and incubated for 2h at 37℃. Wells were washed with PBST and incubated for 1h with anti-APOC3 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50µL stop solution to the wells and read at 450nm immediately. The binding activity of APOC3 and PCYOX1 was shown in Figure 1, and this effect was in a dose dependent manner.

注意事项（Note）

For Research Use Only , Not for Diagnostic Use.